Open Access

Galectin-1 is a diagnostic marker involved in thyroid cancer progression

  • Authors:
    • Vanessa Arcolia
    • Fabrice Journe
    • Aurore Wattier
    • Emmanuelle Leteurtre
    • Florence Renaud
    • Hans-Joachim Gabius
    • Myriam Remmelink
    • Christine Decaestecker
    • Alexandra Rodriguez
    • Sébastien Boutry
    • Sophie Laurent
    • Sven Saussez
  • View Affiliations

  • Published online on: July 4, 2017     https://doi.org/10.3892/ijo.2017.4065
  • Pages: 760-770
  • Copyright: © Arcolia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fine-needle aspiration (FNA) is the most commonly used pre-operative technique for diagnosis of malignant thyroid tumor. However, many benign lesions, with indeterminate diagnosis following FNA, are referred to surgery. Based on multifunctionality of the endogenous galectin-1, we aimed to assess its status for early diagnosis of thyroid cancer. Immunohistochemistry for galectin-1 and -3 was performed on a clinical series of 69 cases of thyroid lesions. Galectin-1 expression was further examined in two additional tissue microarrays (TMA) composed of 66 follicular adenomas and 66 papillary carcinomas in comparison to galectin-3 and cytokeratin-19 (CK19). In addition, a knockdown of galectin-1 in papillary (TPC-1) and anaplastic (8505C) thyroid cancer cell lines was achieved by lentiviral transduction for in vitro experiments. A murine orthotopic thyroid cancer model was used to investigate tumor growth and metastatic ability. Immunohistochemical analyses of galectin-1 and -3 in the series of 69 cases of thyroid lesions revealed that galectin-1 was completely absent in the epithelial compartment of all benign thyroid lesions. Levels of both galectins significantly increased in the cytoplasmic compartment of malignant thyroid cells. Galectin-1 expression in the TMA yielded an excellent specificity (97%), while galectin-3 and CK19 presented a higher sensitivity (>97%) in discriminating benign from malignant thyroid lesions. In vitro experiments revealed that migration was negatively affected in TPC-1 galectin-1 knockdown (KD) cells, and that proliferation and invasion capacity of 8505C cells decreased after galectin-1 KD. Moreover, an orthotopic mouse model displayed a lower rate of tumor development with galectin-1 KD thyroid anaplastic cancer cells than in the control. Our findings support the introduction of galectin-1 as a reliable diagnostic marker for thyroid carcinomas. Its involvement in cell proliferation, migration, invasion and tumor growth also intimate functional involvement of galectin-1 in the progression of thyroid carcinoma, suggesting its potential as a therapeutic target.
View Figures
View References

Related Articles

Journal Cover

September 2017
Volume 51 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Arcolia, V., Journe, F., Wattier, A., Leteurtre, E., Renaud, F., Gabius, H. ... Saussez, S. (2017). Galectin-1 is a diagnostic marker involved in thyroid cancer progression. International Journal of Oncology, 51, 760-770. https://doi.org/10.3892/ijo.2017.4065
MLA
Arcolia, V., Journe, F., Wattier, A., Leteurtre, E., Renaud, F., Gabius, H., Remmelink, M., Decaestecker, C., Rodriguez, A., Boutry, S., Laurent, S., Saussez, S."Galectin-1 is a diagnostic marker involved in thyroid cancer progression". International Journal of Oncology 51.3 (2017): 760-770.
Chicago
Arcolia, V., Journe, F., Wattier, A., Leteurtre, E., Renaud, F., Gabius, H., Remmelink, M., Decaestecker, C., Rodriguez, A., Boutry, S., Laurent, S., Saussez, S."Galectin-1 is a diagnostic marker involved in thyroid cancer progression". International Journal of Oncology 51, no. 3 (2017): 760-770. https://doi.org/10.3892/ijo.2017.4065